Leukemia

Infrequent rearrangement of the STAT5b locus in primary human hematologic malignancies Figure 1
Example of a Southern blot analysis of bone marrow DNA from three leukemic cases (AML2; CML; MDS) and a control DNA digested with BglII, HindIII or EcoRI. Compared to the control, the hybridization patterns obtained with the STAT5b cDNA probe were identical in all leukemic cases. 
TO THE EDITOR
We have previously reported on an original gene fusion between STAT5b and the retinoic acid receptor alpha (RAR␣) in a patient with an acute promyelocytic leukemia-like phenotype (APL-L).
1 A large number of transcription factors have been involved in the development and/or the progression of leukemia. The STAT (signal transducer and activator of transcription) family of transcription factors is composed of seven members in which STAT5 (a and b both mapped on 17q11.2) was shown to be activated by cytokines that regulate proliferation and differentiation in all hematopoietic lineages.
2 Receptors without intrinsic tyrosine kinase activity are coupled with Jak proteins, a family of cytoplasmic tyrosine kinase. Activated Jak proteins phosphorylate the cytoplasmic tail of the receptor that serves as a docking site for STAT proteins. After tyrosine phosphorylation, STAT proteins dimerize, translocate to the nucleus and regulate expression of gene containing interferon responsive elements sequences in their promoters.
To date, four chromosomal rearrangements have been described in APL that juxtapose the RAR␣ coding region to PML (promyelocytic leukemia), PLZF (promyelocytic leukemia zinc finger), NPM (nucleophosmin) and NuMA (nuclear mitotic apparatus).
3 The STAT5b-RAR␣ gene fusion is the first structural STAT gene rearrangement associated with a human tumor.
In order to determine whether STAT5b gene rearrangement is frequently involved in leukemogenesis, we investigated a series of 135 patients with primary leukemia at the chromosomal level using FISH analysis (fluorescence in situ hybridization) with a STAT5b-containing PAC probe and/or at the molecular level using Southern blot analysis with a STAT5b cDNA probe. Thirty-six cases (20%) harbored a chromosome 17q proximal abnormality, of which 31 were tested for chromosomal rearrangement within the STAT5b locus by FISH. In this set of leukemias associated with chromosome 17 abnormality, we failed to detect any STAT5b rearrangement by FISH. In each case, two STAT5b signals were always localized on 17q12 and not involved in the rearrangement. A Southern blot-based screening strategy was subsequently used. Our attempt to find recurrent STAT5b gene rearrangements was also unsuccessful on a total of 121 leukemic patients (Figure 1 ). Using the Southern blot-based method with a STAT5b cDNA probe, we were not able to discriminate between the highly homologous STAT5a and STAT5b genes (93% at the protein level) with certainty. However, no rearranged band was observed using this STAT5b cDNA probe among the 121 cases tested.
Altogether, we found no evidence for STAT5b rearrangement, neither at the chromosomal level by FISH, nor at the molecular level by Southern blot analysis, suggesting that structural rearrangements of the STAT5b gene are not frequently involved in leukemogenesis. However, a potential role for STAT factors in leukemogenesis has been suggested by numerous studies which demonstrate a constitutive STAT DNA-binding activity in leukemic cells. 4 Moreover, studies have provided evidence for a critical role for STAT5 in Bcr-Abl-dependent leukemogenesis 5 and in TEL-Jak2 myelo-and lymphoproliferative diseases. 6 Apart from gross genomic rearrangement of the STAT5b locus, one could hypothesize that more subtle mutations (ie substitutions) leading to constitutively activated STAT5 transcription factors could also be involved in leukemogenesis. In a recent study, Yamada et al 7 did not find such mutations in 49 cases. Altogether, these results suggest that the STAT5 activation is probably a secondary event in most leukemias. Procaspases are mainly localized in the cytosol. However, a fraction of procaspase-3 was identified in the mitochondria, in a complex with Hsp60 and Hsp10. A substantial portion of procaspase-2 and -9 was also found in the intermembrane space of the mitochondria. In addition, procaspase-2 was localized to the nucleus 2 and to the Golgi complex, 3 while procaspase-9 was identified in the nucleus.
6
During apoptosis, several active caspases migrate from one cell compartment to another, possibly to cleave specific substrates.
1
Aside from their role in apoptosis, caspases were recently found to be involved in cell differentiation. 4, 5 To determine whether the differentiation process could influence procaspase localization, we used the U937 human leukemic cells triggered to undergo macrophagic differentiation by exposure to phorbol esters.
6 After 72 h, more than 90% of cells demonstrate a differentiated phenotype (not shown). Four subcellular fractions were isolated from parental and TPA-treated cells. Their purity was assessed by immunoblotting using Abs against COX IV and histone H1 which are located to the inner mitochondrial membrane and the nucleus, respectively (Figure 1a) . The Bcl-2 protein, that was located to the nuclear envelope, the endoplasmic reticulum and the outer mitochondrial membrane was absent from the cytosol (Figure 1a) . Thus, isolated fractions were considered to be of sufficient purity for studying the distribution of procaspases by immunoblotting (Figure 1b) . The long isoform of procaspase-2 (48 kDa) was detected in the four cellular fractions from undifferentiated cells. TPA-induced differentiation was associated with a decreased expression of procaspase-2 in whole cell extracts (Figure 1b) . We did not detect any cleavage fragment, nor an increased cleavage activity of the caspase-2 substrate VDVAD-AFC (not shown), suggesting the lack of activation of the enzyme. Interestingly, when studied in cell fractions, expression of procaspase-2 decreased first in the mitochondria, then in the cytosol and the microsomes, while the enzyme accumulated in the nucleus (Figure 1b) . Independent immunoblot analysis of these fractions does not reflect the relative amount of enzyme in each compartment. Therefore, we also examined the cells by fluorescent microscopy, before and 48 h after the beginning of TPA treatment. This analysis confirmed that the pattern of procaspase-2 expression was modified by TPA-induced differentiation. The granular staining observed in the cytoplasm of undifferentiated cells suggested that a large percentage of the enzyme was inside the mitochondria, which was confirmed by colocalization studies. After 48 h of TPA exposure, we observed a more diffuse staining of the cytoplasm and an increased staining of the nucleus (Figure 1c) . In contrast, when using an anti-procaspase-3 Ab, the nuclear staining was not influenced by the differentiation process (Figure 1d ). Nuclear redistribution of procaspase-2 was previously shown to involve its prodomain and could require interaction of the protein with the adaptor molecule RAIDD.
2
Expression of the four other studied enzymes was poorly modified by TPA-induced differentiation when studied in whole cell extracts (Figure 1b ). Procaspase-6 (34 kDa) was the only proenzyme whose localization was limited to the cytosol. Procaspase-3 (32 kDa), procaspase-7 (35 kDa) and procaspase-9 (48 kDa) were detected in the mitochondria. Procaspase-7 was detected in the three other studied fractions. The anti-procaspase-9 Ab revealed a 30 kDa band that may correspond to procaspase-9b isoform.
7 During the differentiation process, expression of this endogenous inhibitor of caspase-9 decreased in the cytosol and mitochondria while procaspase-9 accumulated in the mitochondria and the nucleus (Figure 1b) . When U937 cells
